Company news
Pentixapharm Holding AG news in 2026
Pentixapharm Holding AG's news releases, calls and decks from 2026, newest first.
Pentixapharm Holding AG: Eckert Wagniskapital und Frühphasenfinanzierung GmbH, Purchase of shares by exercising subscription rights
August 17, 2026
Pentixapharm Reports Second Quarter and First Half 2026 Results and Advances Phase 3 Panda Program
August 6, 2026
Pentixapharm Completes Capital Increase – New Shares Placed in Full
July 27, 2026
Pentixapharm Holding AG completes rights offering and private placement with significant oversubscription generating gross proceeds of approx. EUR 20.4 Million already today
July 27, 2026
Pentixapharm Holding AG - Ad-hoc, Rights offering successfully completed, Remaining shares can be subscribed for via private placement
July 23, 2026
Pentixapharm Holding AG: Rights offering successfully completed, remaining shares available for subscription through private placement
July 22, 2026
Pentixapharm Holding AG: Eckert Wagniskapital und Frühphasenfinanzierung GmbH, Granting of 8.922.464 Subscription rights
July 9, 2026
Pentixapharm Receives FDA Fast Track Designation for Phase 3 Diagnostic Candidate [⁶⁸Ga]Ga-PentixaFor in Primary Aldosteronism
July 9, 2026
Pentixapharm Holding AG: Pentixapharm Receives FDA Fast Track Designation for [⁶⁸Ga]Ga-PentixaFor for the Subtyping of Primary Aldosteronism
July 9, 2026
Pentixapharm Launches Rights Issue to Fund PANDA Phase 3 and U.S. Expansion
July 1, 2026
Pentixapharm Holding AG: Resolves on Rights Issue with an Offering Volume of up to Appr. EUR 20.4 Million; Major Shareholder Eckert Wagniskapital Commits to Fully Exercise Its Subscription Rights
July 1, 2026
Pentixapharm Announces FDA Clearance of IND for Phase 3 PANDA Study of First-in-Class Cardiovascular Diagnostic Program
June 9, 2026
Pentixapharm Announces IND Submission to FDA for Phase 3 PANDA Study of First-in-Class CXCR4-Targeted Cardiovascular Diagnostic
May 11, 2026
Pentixapharm Announces IND Submission to FDA for Phase 3 PANDA Study of First-in-Class CXCR4-Targeted Cardiovascular Diagnostic
May 10, 2026
Pentixapharm Reports First Quarter 2026 Results and Highlights Clinical and Regulatory Momentum
May 7, 2026
Pentixapharm Reports First Quarter 2026 Results and Highlights Clinical and Regulatory Momentum
May 6, 2026
Financial document (Pentixapharm Q1 2026 e)
May 6, 2026
Financial document (Presentation Earnings Call March 2026 PTX)
April 2, 2026
Pentixapharm Holding AG Appoints Erik Merten to the Executive Board
March 31, 2026
Pentixapharm Appoints Erik Merten to the Executive Board
March 30, 2026
Pentixapharm Holding AG will publish its financial report for the 2025 fiscal year on March 26, 2026
March 19, 2026
Pentixapharm Receives FDA “Study May Proceed” Letters for Dual Theranostic INDs in CXCR4-Based Hemato-Oncology Program
February 25, 2026
Pentixapharm Receives FDA “Study May Proceed” Letters for Dual Theranostic INDs in CXCR4-Based Hemato-Oncology Program
February 25, 2026
Pentixapharm Announces Peer-Reviewed Phase 2 Data Back Use of PENTIXAFOR as a Superior Non-invasive PET-Diagnostic for Primary Aldosteronism
February 5, 2026
Pentixapharm Receives FDA Feedback for Phase 3 Diagnostic Study in Hypertension
January 7, 2026
Pentixapharm Receives FDA Feedback for Phase 3 Diagnostic Study in Hypertension
January 6, 2026
Decks in 2026
- FY2025 Earnings Presentation
Earnings · 27 slides · Mar 26, 2026